No Data
Rockwell Medical: Profitability Path and Cash-Flow Upside Drive Reiterated Buy Rating and Unchanged $2 Price Target
H.C. Wainwright Maintains Rockwell Medical(RMTI.US) With Buy Rating, Maintains Target Price $2
Rockwell Medical Faces Nasdaq Compliance Challenge, Eyes Reverse Split
Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT) and Cognition Therapeutics (CGTX)
Rockwell Medical Outlines $70M-$75M 2026 Net Sales Outlook While Targeting Positive Net Income in H2 2026
Rockwell Medical Issues Updated Investor Corporate Presentation